

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 15, 2025

OCI-AML-3

RRID:CVCL_1844

Type: Cell Line

Proper Citation

(RRID:CVCL_1844)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1844

Proper Citation: (RRID:CVCL_1844)

Sex: Male

Defining Citation: [PMID:2538684](#), [PMID:12393637](#), [PMID:16079892](#), [PMID:16408098](#), [PMID:21552520](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26434589](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28109323](#), [PMID:29491412](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31739141](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: H3K27ac ChIP-seq epigenome analysis., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: OCI-AML-3

Synonyms: OCI-Aml-3, OCI/AML-3, OCI-AML3, OCI/AML3, OCI AML3, OCIAML3, Ontario Cancer Institute-Acute Myeloid Leukemia-3

Cross References: BTO:BTO_0004620, CLO:CLO_0009853, EFO:EFO_0006289, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:214,

BioSample:SAMN03473107, BioSample:SAMN10988470, cancercellines:CVCL_1844, CCTCC:GDC0216, Cell_Model_Passport:SIDM00462, ChEMBL-Cells:ChEMBL4295392, ChEMBL-Targets:ChEMBL4296479, Cosmic:787467, Cosmic:975289, Cosmic:1012110, Cosmic:1127258, Cosmic:1245831, Cosmic:1319546, Cosmic:1557602, Cosmic:1582387, Cosmic:1696140, Cosmic:1779129, Cosmic:2131552, Cosmic:2306232, Cosmic:2750869, Cosmic-CLP:1290455, DepMap:ACH-000336, DSMZ:ACC-582, DSMZCellDive:ACC-582, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1290455, GEO:GSM482512, GEO:GSM887469, GEO:GSM888549, GEO:GSM1446756, GEO:GSM1525022, GEO:GSM1670296, GEO:GSM2716711, GEO:GSM2716712, GEO:GSM2716774, GEO:GSM2716775, GEO:GSM2716776, GEO:GSM2716777, IARC_TP53:30132, LiGeA:CCLE_569, LINCS_LDP:LCL-1066, Lonza:530, PharmacDB:OCIAML3_1184_2019, Progenetix:CVCL_1844, PubChem_Cell_line:CVCL_1844, Ubigen:YC-C022, Wikidata:Q54931742

ID: CVCL_1844

Record Creation Time: 20250131T202145+0000

Record Last Update: 20250131T203959+0000

Ratings and Alerts

No rating or validation information has been found for OCI-AML-3.

No alerts have been found for OCI-AML-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 261 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. *Molecular cancer*, 23(1), 120.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. *Cancer cell*, 42(5), 850.

Zhu J, et al. (2024) The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. *The FEBS journal*.

Patterson SD, et al. (2024) The MYC-NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells. *Molecular oncology*.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Djordjevic S, et al. (2024) STIM2 is involved in the regulation of apoptosis and the cell cycle in normal and malignant monocytic cells. *Molecular oncology*.

Bueno MLP, et al. (2024) α -Carboline derivatives are potent against Acute Myeloid Leukemia in vitro and in vivo. *Pharmacological reports* : PR, 76(4), 838.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. *Cancer research*, 84(6), 905.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

von Palffy S, et al. (2023) The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML. *Blood advances*, 7(7), 1204.

Hattori T, et al. (2023) Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. *Cancer discovery*, 13(1), 132.

Muranyi A, et al. (2023) Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. *Blood advances*, 7(3), 351.

Fiskus W, et al. (2023) Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. *Blood cancer journal*, 13(1), 53.

Feng Y, et al. (2023) Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1-mutated acute myeloid leukemia. *Acta pharmaceutica Sinica. B*, 13(2), 598.

Wang XQD, et al. (2023) Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia. *Cancer discovery*, 13(3), 724.

Komata Y, et al. (2023) MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins. *Nature communications*, 14(1), 1979.

Pitts HA, et al. (2023) SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response. *International journal of molecular sciences*, 24(11).

Carter BZ, et al. (2023) Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.

Blood cancer journal, 13(1), 57.

Marcotegui N, et al. (2023) Set Protein Is Involved in FLT3 Membrane Trafficking. Cancers, 15(8).

Maru B, et al. (2023) PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy. Cell reports. Medicine, 4(9), 101191.